» Articles » PMID: 38543651

A Mini-Review on the Common Antiviral Drug Targets of Coronavirus

Overview
Journal Microorganisms
Specialty Microbiology
Date 2024 Mar 28
PMID 38543651
Authors
Affiliations
Soon will be listed here.
Abstract

Coronaviruses in general are a zoonotic pathogen with significant cross-species transmission. They are widely distributed in nature and have recently become a major threat to global public health. Vaccines are the preferred strategy for the prevention of coronaviruses. However, the rapid rate of virus mutation, large number of prevalent strains, and lag in vaccine development contribute to the continuing frequent occurrence of coronavirus diseases. There is an urgent need for new antiviral strategies to address coronavirus infections effectively. Antiviral drugs are important in the prevention and control of viral diseases. Members of the genus coronavirus are highly similar in life-cycle processes such as viral invasion and replication. These, together with the high degree of similarity in the protein sequences and structures of viruses in the same genus, provide common targets for antiviral drug screening of coronaviruses and have led to important advances in recent years. In this review, we summarize the pathogenic mechanisms of coronavirus, common drugs targeting coronavirus entry into host cells, and common drug targets against coronaviruses based on biosynthesis and on viral assembly and release. We also describe the common targets of antiviral drugs against coronaviruses and the progress of antiviral drug research. Our aim is to provide a theoretical basis for the development of antiviral drugs and to accelerate the development and utilization of commonly used antiviral drugs in China.

Citing Articles

Arylamines QSAR-Based Design and Molecular Dynamics of New Phenylthiophene and Benzimidazole Derivatives with Affinity for the C111, Y268, and H73 Sites of SARS-CoV-2 PLpro Enzyme.

Sabadini G, Mellado M, Morales C, Mella J Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794177 PMC: 11124164. DOI: 10.3390/ph17050606.

References
1.
Yuan S, Gao X, Tang K, Cai J, Hu M, Luo P . Targeting papain-like protease for broad-spectrum coronavirus inhibition. Protein Cell. 2022; 13(12):940-953. PMC: 8983325. DOI: 10.1007/s13238-022-00909-3. View

2.
Yazdi A, Pakarian P, Perveen S, Hajian T, Santhakumar V, Bolotokova A . Kinetic Characterization of SARS-CoV-2 nsp13 ATPase Activity and Discovery of Small-Molecule Inhibitors. ACS Infect Dis. 2022; 8(8):1533-1542. DOI: 10.1021/acsinfecdis.2c00165. View

3.
Runfeng L, Yunlong H, Jicheng H, Weiqi P, Qinhai M, Yongxia S . Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res. 2020; 156:104761. PMC: 7102548. DOI: 10.1016/j.phrs.2020.104761. View

4.
Zeng J, Weissmann F, Bertolin A, Posse V, Canal B, Ulferts R . Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase. Biochem J. 2021; 478(13):2405-2423. PMC: 8286831. DOI: 10.1042/BCJ20210201. View

5.
Lu L, Su S, Yang H, Jiang S . Antivirals with common targets against highly pathogenic viruses. Cell. 2021; 184(6):1604-1620. DOI: 10.1016/j.cell.2021.02.013. View